                         SEQUENCE LISTING

<110>  Telix International Pty Ltd
 
<120>  Antibodies

<130>  53082446SCH

<140>  2019902343
<141>  2020-06-10

<150>  2019902343
<151>  2019-07-02

<160>  243   

<170>  PatentIn version 3.5

<210>  1
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANT4044 Variable Heavy chain - HCDR1 (protein)

<400>  1

Glu Tyr Thr Ile His 
1               5   


<210>  2
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANT4044 Variable Heavy chain - HCDR2 (protein)

<400>  2

Asn Ile Asn Pro Asn Asn Gly Gly Thr Thr Tyr Asn Gln Lys Phe Glu 
1               5                   10                  15      


Asp 
    


<210>  3
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANT4044 Variable Heavy chain - HCDR3 (protein)

<400>  3

Gly Trp Asn Phe Asp Tyr 
1               5       


<210>  4
<211>  115
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANT4044 Variable Heavy chain - VH (protein)

<400>  4

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr 
            20                  25                  30          


Thr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asn Ile Asn Pro Asn Asn Gly Gly Thr Thr Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Glu Asp Arg Val Thr Ile Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Ala Gly Trp Asn Phe Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr 
            100                 105                 110         


Val Ser Ser 
        115 


<210>  5
<211>  15
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  ANT4044 Variable Heavy chain - HCDR1 (DNA)

<400>  5
gaatacacca tccac                                                        15


<210>  6
<211>  51
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  ANT4044 Variable Heavy chain - HCDR2 (DNA)

<400>  6
aacattaatc ctaacaatgg tggtactacc tacaaccaga agttcgagga c                51


<210>  7
<211>  18
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  ANT4044 Variable Heavy chain - HCDR3 (DNA)

<400>  7
ggttggaact ttgactac                                                     18


<210>  8
<211>  345
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  ANT4044 Variable Heavy chain - VH (DNA)

<400>  8
gaggtccagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc       60

tcctgcaagg cttctggata cacattcact gaatacacca tccactgggt gaggcaggcc      120

cctggaaagg gccttgagtg gattggaaac attaatccta acaatggtgg tactacctac      180

aaccagaagt tcgaggacag agtcacaatc actgtagaca agtccaccag cacagcctac      240

atggagctca gcagcctgag atctgaggat actgcagtct attactgtgc agctggttgg      300

aactttgact actggggcca aggcaccacg gtcaccgtct cctca                      345


<210>  9
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANT4044 Variable Heavy chain - HFR1 (protein)

<400>  9

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr 
            20                  25                  30  


<210>  10
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANT4044 Variable Heavy chain - HFR2 (protein)

<400>  10

Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly 
1               5                   10                  


<210>  11
<211>  32
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANT4044 Variable Heavy chain - HFR3 (protein)

<400>  11

Arg Val Thr Ile Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu 
1               5                   10                  15      


Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 
            20                  25                  30          


<210>  12
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANT4044 Variable Heavy chain - HFR4 (protein)

<400>  12

Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
1               5                   10      


<210>  13
<211>  90
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  ANT4044 Variable Heavy chain - HFR1 (DNA)

<400>  13
gaggtccagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc       60

tcctgcaagg cttctggata cacattcact                                        90


<210>  14
<211>  42
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  ANT4044 Variable Heavy chain - HFR2 (DNA)

<400>  14
tgggtgaggc aggcccctgg aaagggcctt gagtggattg ga                          42


<210>  15
<211>  96
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  ANT4044 Variable Heavy chain - HFR3 (DNA)

<400>  15
agagtcacaa tcactgtaga caagtccacc agcacagcct acatggagct cagcagcctg       60

agatctgagg atactgcagt ctattactgt gcagct                                 96


<210>  16
<211>  33
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  ANT4044 Variable Heavy chain - HFR4 (DNA)

<400>  16
tggggccaag gcaccacggt caccgtctcc tca                                    33


<210>  17
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANT4044-A2 Variable Heavy chain - HCDR1 (protein)

<400>  17

Glu Tyr Thr Ile His 
1               5   


<210>  18
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANT4044-A2 Variable Heavy chain - HCDR2 (protein)

<400>  18

Asn Ile Asn Pro Asn Asn Gly Gly Thr Thr Tyr Asn Gln Lys Phe Glu 
1               5                   10                  15      


Asp 
    


<210>  19
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANT4044-A2 Variable Heavy chain - HCDR3 (protein)

<400>  19

Tyr Trp Leu Phe Asp Tyr 
1               5       


<210>  20
<211>  115
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANT4044-A2 Variable Heavy chain - VH (protein)

<400>  20

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr 
            20                  25                  30          


Thr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asn Ile Asn Pro Asn Asn Gly Gly Thr Thr Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Glu Asp Arg Val Thr Ile Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Ala Tyr Trp Leu Phe Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr 
            100                 105                 110         


Val Ser Ser 
        115 


<210>  21
<211>  15
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  ANT4044-A2 Variable Heavy chain - HCDR1 (DNA)

<400>  21
gaatacacca tccac                                                        15


<210>  22
<211>  51
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  ANT4044-A2 Variable Heavy chain - HCDR2 (DNA)

<400>  22
aacattaatc ctaacaatgg tggtactacc tacaaccaga agttcgagga c                51


<210>  23
<211>  18
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  ANT4044-A2 Variable Heavy chain - HCDR3 (DNA)

<400>  23
tactggctgt tcgactac                                                     18


<210>  24
<211>  345
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  ANT4044-A2 Variable Heavy chain - VH (DNA)

<400>  24
gaggtccagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc       60

tcctgcaagg cttctggata cacattcact gaatacacca tccactgggt gaggcaggcc      120

cctggaaagg gccttgagtg gattggaaac attaatccta acaatggtgg tactacctac      180

aaccagaagt tcgaggacag agtcacaatc actgtagaca agtccaccag cacagcctac      240

atggagctca gcagcctgag atctgaggat actgcagtct attactgtgc agcttactgg      300

ctgttcgact actggggcca aggcaccacg gtcaccgtct cctca                      345


<210>  25
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANT4044-A2 Variable Heavy chain - HFR1 (protein)

<400>  25

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr 
            20                  25                  30  


<210>  26
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANT4044-A2 Variable Heavy chain - HFR2 (protein)

<400>  26

Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly 
1               5                   10                  


<210>  27
<211>  32
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANT4044-A2 Variable Heavy chain - HFR3 (protein)

<400>  27

Arg Val Thr Ile Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu 
1               5                   10                  15      


Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 
            20                  25                  30          


<210>  28
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANT4044-A2 Variable Heavy chain - HFR4 (protein)

<400>  28

Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
1               5                   10      


<210>  29
<211>  90
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  ANT4044-A2 Variable Heavy chain - HFR1 (DNA)

<400>  29
gaggtccagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc       60

tcctgcaagg cttctggata cacattcact                                        90


<210>  30
<211>  42
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  ANT4044-A2 Variable Heavy chain - HFR2 (DNA)

<400>  30
tgggtgaggc aggcccctgg aaagggcctt gagtggattg ga                          42


<210>  31
<211>  96
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  ANT4044-A2 Variable Heavy chain - HFR3 (DNA)

<400>  31
agagtcacaa tcactgtaga caagtccacc agcacagcct acatggagct cagcagcctg       60

agatctgagg atactgcagt ctattactgt gcagct                                 96


<210>  32
<211>  33
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  ANT4044-A2 Variable Heavy chain - HFR4 (DNA)

<400>  32
tggggccaag gcaccacggt caccgtctcc tca                                    33


<210>  33
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANT4044/ ANT4044-A2 Variable Light chain - LCDR1 (protein)

<400>  33

Lys Ala Ser Gln Asp Val Gly Thr Ala Val Asp 
1               5                   10      


<210>  34
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANT4044/ ANT4044-A2 Variable Light chain - LCDR2 (protein)

<400>  34

Trp Ala Ser Thr Arg His Thr 
1               5           


<210>  35
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANT4044/ ANT4044-A2 Variable Light chain - LCDR3 (protein)

<400>  35

Gln Gln Tyr Asn Ser Tyr Pro Leu Thr 
1               5                   


<210>  36
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANT4044/ ANT4044-A2 Variable Light chain - VL (protein)

<400>  36

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Ala 
            20                  25                  30          


Val Asp Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Leu 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys 
            100                 105         


<210>  37
<211>  33
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  ANT4044/ ANT4044-A2 Variable Light chain - LCDR1 (DNA)

<400>  37
aaggccagtc aggatgtggg tactgctgta gac                                    33


<210>  38
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  ANT4044/ ANT4044-A2 Variable Light chain - LCDR2 (DNA)

<400>  38
tgggcatcca cccggcacac t                                                 21


<210>  39
<211>  27
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  ANT4044/ ANT4044-A2 Variable Light chain - LCDR3 (DNA)

<400>  39
cagcaatata acagctatcc tctcacg                                           27


<210>  40
<211>  321
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  ANT4044/ ANT4044-A2 Variable Light chain - VL (DNA)

<400>  40
gacattcaga tgacccagtc tcccagcacc ctgtccgcat cagtaggaga cagggtcacc       60

atcacttgca aggccagtca ggatgtgggt actgctgtag actggtatca acagaaacca      120

gggcaagctc ctaaactact gatttactgg gcatccaccc ggcacactgg agtccctgat      180

cgcttcagcg gcagtggatc tgggacagat ttcactctca ccatcagcag actgcagcct      240

gaagactttg cagtttatta ctgtcagcaa tataacagct atcctctcac gttcggccag      300

gggaccaagg tggatatcaa a                                                321


<210>  41
<211>  23
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANT4044/ ANT4044-A2 Variable Light chain - LFR1 (protein)

<400>  41

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys 
            20              


<210>  42
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANT4044/ ANT4044-A2 Variable Light chain - LFR2 (protein)

<400>  42

Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Leu Ile Tyr 
1               5                   10                  15  


<210>  43
<211>  32
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANT4044/ ANT4044-A2 Variable Light chain - LFR3 (protein)

<400>  43

Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 
1               5                   10                  15      


Leu Thr Ile Ser Arg Leu Gln Pro Glu Asp Phe Ala Val Tyr Tyr Cys 
            20                  25                  30          


<210>  44
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANT4044/ ANT4044-A2 Variable Light chain - LFR4 (protein)

<400>  44

Phe Gly Gln Gly Thr Lys Val Asp Ile Lys 
1               5                   10  


<210>  45
<211>  69
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  ANT4044/ ANT4044-A2 Variable Light chain - LFR1

(DNA)

<400>  45
gacattcaga tgacccagtc tcccagcacc ctgtccgcat cagtaggaga cagggtcacc       60

atcacttgc                                                               69


<210>  46
<211>  45
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  ANT4044/ ANT4044-A2 Variable Light chain - LFR2(DNA)

<400>  46
tggtatcaac agaaaccagg gcaagctcct aaactactga tttac                       45


<210>  47
<211>  96
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  ANT4044/ ANT4044-A2 Variable Light chain - LFR3 (DNA)

<400>  47
ggagtccctg atcgcttcag cggcagtgga tctgggacag atttcactct caccatcagc       60

agactgcagc ctgaagactt tgcagtttat tactgt                                 96


<210>  48
<211>  30
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  ANT4044/ ANT4044-A2 Variable Light chain - LFR4 (DNA)

<400>  48
ttcggccagg ggaccaaggt ggatatcaaa                                        30


<210>  49
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab chimeric VHO Variable Heavy chain - HCDR1 (protein)

<400>  49

Asn Tyr Tyr Met Ser 
1               5   


<210>  50
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab chimeric VHO Variable Heavy chain - HCDR2 (protein)

<400>  50

Ala Ile Asn Ser Asp Gly Gly Ile Thr Tyr Tyr Leu Asp Thr Val Lys 
1               5                   10                  15      


Gly 
    


<210>  51
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab chimeric VHO Variable Heavy chain - HCDR3 (protein)

<400>  51

His Arg Ser Gly Tyr Phe Ser Met Asp Tyr 
1               5                   10  


<210>  52
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab chimeric VHO Variable Heavy chain - VH (protein)

<400>  52

Asp Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Leu Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 
            20                  25                  30          


Tyr Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Leu Val 
        35                  40                  45              


Ala Ala Ile Asn Ser Asp Gly Gly Ile Thr Tyr Tyr Leu Asp Thr Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Leu Phe Tyr Cys 
                85                  90                  95      


Ala Arg His Arg Ser Gly Tyr Phe Ser Met Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Ser Val Thr Val Ser Ser 
        115                 


<210>  53
<211>  15
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab chimeric VHO Variable Heavy chain - HCDR1 (DNA)

<400>  53
aactattaca tgtct                                                        15


<210>  54
<211>  51
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab chimeric VHO Variable Heavy chain - HCDR2 (DNA)

<400>  54
gccattaata gtgatggtgg tatcacctac tatctagaca ctgtgaaggg c                51


<210>  55
<211>  30
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab chimeric VHO Variable Heavy chain - HCDR3 (DNA)

<400>  55
caccgctcgg gctacttttc tatggactac                                        30


<210>  56
<211>  357
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab chimeric VHO Variable Heavy chain - VH (DNA)

<400>  56
gacgtgaagc tcgtggagtc tgggggaggc ttagtgaagc ttggaggatc cctgaaactc       60

tcctgtgcag cctctggatt cactttcagt aactattaca tgtcttgggt tcgccagact      120

ccagagaaga ggctggagtt ggtcgcagcc attaatagtg atggtggtat cacctactat      180

ctagacactg tgaagggccg attcaccatt tcaagagaca atgccaagaa caccctgtac      240

ctgcaaatga gcagtctgaa gtctgaggac acagccttgt tttactgtgc aagacaccgc      300

tcgggctact tttctatgga ctactggggt caaggaacct cagtcaccgt ctcctca         357


<210>  57
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab chimeric VHO Variable Heavy chain - HFR1 (protein)

<400>  57

Asp Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Leu Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser 
            20                  25                  30  


<210>  58
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab chimeric VHO Variable Heavy chain - HFR2 (protein)

<400>  58

Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Leu Val Ala 
1               5                   10                  


<210>  59
<211>  32
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab chimeric VHO Variable Heavy chain - HFR3 (protein)

<400>  59

Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln 
1               5                   10                  15      


Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Leu Phe Tyr Cys Ala Arg 
            20                  25                  30          


<210>  60
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab chimeric VHO Variable Heavy chain - HFR4 (protein)

<400>  60

Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser 
1               5                   10      


<210>  61
<211>  90
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab chimeric VHO Variable Heavy chain - HFR1 (DNA)

<400>  61
gacgtgaagc tcgtggagtc tgggggaggc ttagtgaagc ttggaggatc cctgaaactc       60

tcctgtgcag cctctggatt cactttcagt                                        90


<210>  62
<211>  42
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab chimeric VHO Variable Heavy chain - HFR2 (DNA)

<400>  62
tgggttcgcc agactccaga gaagaggctg gagttggtcg ca                          42


<210>  63
<211>  96
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab chimeric VHO Variable Heavy chain - HFR3 (DNA)

<400>  63
cgattcacca tttcaagaga caatgccaag aacaccctgt acctgcaaat gagcagtctg       60

aagtctgagg acacagcctt gttttactgt gcaaga                                 96


<210>  64
<211>  33
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab chimeric VHO Variable Heavy chain - HFR4 (DNA)

<400>  64
tggggtcaag gaacctcagt caccgtctcc tca                                    33


<210>  65
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH1 Variable Heavy chain - HCDR1 (protein)

<400>  65

Asn Tyr Tyr Met Ser 
1               5   


<210>  66
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH1 Variable Heavy chain - HCDR2

<400>  66

Ala Ile Asn Ser Asp Gly Gly Ile Thr Tyr Tyr Leu Asp Thr Val Lys 
1               5                   10                  15      


Gly 
    


<210>  67
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH1 Variable Heavy chain - HCDR3 (protein)

<400>  67

His Arg Ser Gly Tyr Phe Ser Met Asp Tyr 
1               5                   10  


<210>  68
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH1 Variable Heavy chain - VH (protein)

<400>  68

Asp Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 
            20                  25                  30          


Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Leu Val 
        35                  40                  45              


Ala Ala Ile Asn Ser Asp Gly Gly Ile Thr Tyr Tyr Leu Asp Thr Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Leu Tyr Tyr Cys 
                85                  90                  95      


Ala Arg His Arg Ser Gly Tyr Phe Ser Met Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Ser Val Thr Val Ser Ser 
        115                 


<210>  69
<211>  15
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH1 Variable Heavy chain - HCDR1 (DNA)

<400>  69
aactactaca tgagc                                                        15


<210>  70
<211>  51
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH1 Variable Heavy chain - HCDR2 (DNA)

<400>  70
gccattaaca gtgacggtgg catcacctac tacctggaca ccgtgaaggg c                51


<210>  71
<211>  30
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH1 Variable Heavy chain - HCDR3 (DNA)

<400>  71
cacaggagcg gctacttctc tatggactac                                        30


<210>  72
<211>  357
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH1 Variable Heavy chain - VH (DNA)

<400>  72
gacgtgaagc tggtggagtc tgggggaggc ttggtcaagc ctggaggatc cctgagactc       60

tcctgtgcag cctctggatt caccttcagt aactactaca tgagctgggt gcgccaggct      120

ccagggaagg ggctggagct ggttgccgcc attaacagtg acggtggcat cacctactac      180

ctggacaccg tgaagggccg attcaccatc tccagggaca acgccaagaa caccctgtat      240

ctgcaaatga gcagcctgaa gagcgaggac acggccctgt attactgtgc gagacacagg      300

agcggctact tctctatgga ctactggggc cagggcacca gcgtcactgt ctcctca         357


<210>  73
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH1 Variable Heavy chain - HFR1 (protein)

<400>  73

Asp Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser 
            20                  25                  30  


<210>  74
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH1 Variable Heavy chain - HFR2 (protein)

<400>  74

Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Leu Val Ala 
1               5                   10                  


<210>  75
<211>  32
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH1 Variable Heavy chain - HFR3 (protein)

<400>  75

Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln 
1               5                   10                  15      


Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg 
            20                  25                  30          


<210>  76
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH1 Variable Heavy chain - HFR4 (protein)

<400>  76

Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser 
1               5                   10      


<210>  77
<211>  90
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH1 Variable Heavy chain - HFR1 (DNA)

<400>  77
gacgtgaagc tggtggagtc tgggggaggc ttggtcaagc ctggaggatc cctgagactc       60

tcctgtgcag cctctggatt caccttcagt                                        90


<210>  78
<211>  42
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH1 Variable Heavy chain - HFR2 (DNA)

<400>  78
tgggtgcgcc aggctccagg gaaggggctg gagctggttg cc                          42


<210>  79
<211>  96
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH1 Variable Heavy chain - HFR3 (DNA)

<400>  79
cgattcacca tctccaggga caacgccaag aacaccctgt atctgcaaat gagcagcctg       60

aagagcgagg acacggccct gtattactgt gcgaga                                 96


<210>  80
<211>  33
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH1 Variable Heavy chain - HFR4 (DNA)

<400>  80
tggggccagg gcaccagcgt cactgtctcc tca                                    33


<210>  81
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH3 Variable Heavy chain - HCDR1 (protein)

<400>  81

Asn Tyr Tyr Met Ser 
1               5   


<210>  82
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH3 Variable Heavy chain - HCDR2 (protein)

<400>  82

Ala Ile Asn Ser Asp Gly Gly Ile Thr Tyr Tyr Leu Asp Thr Val Lys 
1               5                   10                  15      


Gly 
    


<210>  83
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH3 Variable Heavy chain - HCDR3 (protein)

<400>  83

His Arg Ser Gly Tyr Phe Ser Met Asp Tyr 
1               5                   10  


<210>  84
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH3 Variable Heavy chain - VH (protein)

<400>  84

Asp Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 
            20                  25                  30          


Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Leu Val 
        35                  40                  45              


Ala Ala Ile Asn Ser Asp Gly Gly Ile Thr Tyr Tyr Leu Asp Thr Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 
                85                  90                  95      


Ala Arg His Arg Ser Gly Tyr Phe Ser Met Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ser 
        115                 


<210>  85
<211>  15
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH3 Variable Heavy chain - HCDR1 (DNA)

<400>  85
aactactaca tgagc                                                        15


<210>  86
<211>  50
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH3 Variable Heavy chain - HCDR2 (DNA)

<400>  86
ccattaacag tgacggtggc atcacctact acctggacac cgtgaagggc                  50


<210>  87
<211>  30
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH3 Variable Heavy chain - HCDR3 (DNA)

<400>  87
cacaggagcg gctacttctc tatggactac                                        30


<210>  88
<211>  357
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH3 Variable Heavy chain - VH (DNA)

<400>  88
gacgtgaagc tggtggagtc tgggggaggc ttggtcaagc ctggaggatc cctgagactc       60

tcctgtgcag cctctggatt caccttcagt aactactaca tgagctgggt gcgccaggct      120

ccagggaagg ggctggagct ggttgccgcc attaacagtg acggtggcat cacctactac      180

ctggacaccg tgaagggccg attcaccatc tccagggaca acgccaagaa caccctgtat      240

ctgcaaatga acagcctgag ggccgaggac acggccctgt attactgtgc gagacacagg      300

agcggctact tctctatgga ctactggggc cagggcaccc tggtcactgt ctcctca         357


<210>  89
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH3 Variable Heavy chain - HFR1 (protein)

<400>  89

Asp Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser 
            20                  25                  30  


<210>  90
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH3 Variable Heavy chain - HFR2 (protein)

<400>  90

Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Leu Val Ala 
1               5                   10                  


<210>  91
<211>  32
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH3 Variable Heavy chain - HFR3 (protein)

<400>  91

Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln 
1               5                   10                  15      


Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg 
            20                  25                  30          


<210>  92
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH3 Variable Heavy chain - HFR4 (protein)

<400>  92

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
1               5                   10      


<210>  93
<211>  90
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH3 Variable Heavy chain - HFR1 (DNA)

<400>  93
gacgtgaagc tggtggagtc tgggggaggc ttggtcaagc ctggaggatc cctgagactc       60

tcctgtgcag cctctggatt caccttcagt                                        90


<210>  94
<211>  42
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH3 Variable Heavy chain - HFR2 (DNA)

<400>  94
tgggtgcgcc aggctccagg gaaggggctg gagctggttg cc                          42


<210>  95
<211>  96
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH3 Variable Heavy chain - HFR3 (DNA)

<400>  95
cgattcacca tctccaggga caacgccaag aacaccctgt atctgcaaat gaacagcctg       60

agggccgagg acacggccct gtattactgt gcgaga                                 96


<210>  96
<211>  33
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH3 Variable Heavy chain - HFR4 (DNA)

<400>  96
tggggccagg gcaccctggt cactgtctcc tca                                    33


<210>  97
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH4 Variable Heavy chain - HCDR1 (protein)

<400>  97

Asn Tyr Tyr Met Ser 
1               5   


<210>  98
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH4 Variable Heavy chain - HCDR2 (protein)

<400>  98

Ala Ile Asn Ser Asp Gly Gly Ile Thr Tyr Tyr Leu Asp Thr Val Lys 
1               5                   10                  15      


Gly 
    


<210>  99
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH4 Variable Heavy chain - HCDR3 (protein)

<400>  99

His Arg Ser Gly Tyr Phe Ser Met Asp Tyr 
1               5                   10  


<210>  100
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH4 Variable Heavy chain - VH (protein)

<400>  100

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 
            20                  25                  30          


Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Leu Val 
        35                  40                  45              


Ala Ala Ile Asn Ser Asp Gly Gly Ile Thr Tyr Tyr Leu Asp Thr Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 
                85                  90                  95      


Ala Arg His Arg Ser Gly Tyr Phe Ser Met Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ser 
        115                 


<210>  101
<211>  15
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH4 Variable Heavy chain - HCDR1 (DNA)

<400>  101
aactactaca tgagc                                                        15


<210>  102
<211>  51
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH4 Variable Heavy chain - HCDR2 (DNA)

<400>  102
gccattaaca gtgacggtgg catcacctac tacctggaca ccgtgaaggg c                51


<210>  103
<211>  30
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH4 Variable Heavy chain - HCDR3 (DNA)

<400>  103
cacaggagcg gctacttctc tatggactac                                        30


<210>  104
<211>  357
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH4 Variable Heavy chain - VH (DNA)

<400>  104
gaggtgcagc tggtggagtc tgggggaggc ttggtcaagc ctggaggatc cctgagactc       60

tcctgtgcag cctctggatt caccttcagt aactactaca tgagctgggt gcgccaggct      120

ccagggaagg ggctggagct ggttgccgcc attaacagtg acggtggcat cacctactac      180

ctggacaccg tgaagggccg attcaccatc tccagggaca acgccaagaa caccctgtat      240

ctgcaaatga acagcctgag ggccgaggac acggccctgt attactgtgc gagacacagg      300

agcggctact tctctatgga ctactggggc cagggcaccc tggtcactgt ctcctca         357


<210>  105
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH4 Variable Heavy chain - HFR1 (protein)

<400>  105

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser 
            20                  25                  30  


<210>  106
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH4 Variable Heavy chain - HFR2 (protein)

<400>  106

Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Leu Val Ala 
1               5                   10                  


<210>  107
<211>  32
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH4 Variable Heavy chain - HFR3 (protein)

<400>  107

Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln 
1               5                   10                  15      


Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg 
            20                  25                  30          


<210>  108
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH4 Variable Heavy chain - HFR4 (protein)

<400>  108

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
1               5                   10      


<210>  109
<211>  90
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH4 Variable Heavy chain - HFR1 (DNA)

<400>  109
gaggtgcagc tggtggagtc tgggggaggc ttggtcaagc ctggaggatc cctgagactc       60

tcctgtgcag cctctggatt caccttcagt                                        90


<210>  110
<211>  42
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH4 Variable Heavy chain - HFR2 (DNA)

<400>  110
tgggtgcgcc aggctccagg gaaggggctg gagctggttg cc                          42


<210>  111
<211>  96
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH4 Variable Heavy chain - HFR3 (DNA)

<400>  111
cgattcacca tctccaggga caacgccaag aacaccctgt atctgcaaat gaacagcctg       60

agggccgagg acacggccct gtattactgt gcgaga                                 96


<210>  112
<211>  33
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH4 Variable Heavy chain - HFR4 (DNA)

<400>  112
tggggccagg gcaccctggt cactgtctcc tca                                    33


<210>  113
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH5 Variable Heavy chain - HCDR1 (protein)

<400>  113

Asn Tyr Tyr Met Ser 
1               5   


<210>  114
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH5 Variable Heavy chain - HCDR2 (protein)

<400>  114

Ala Ile Asn Ser Asp Gly Gly Ile Thr Tyr Tyr Leu Asp Thr Val Lys 
1               5                   10                  15      


Gly 
    


<210>  115
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH5 Variable Heavy chain - HCDR3 (protein)

<400>  115

His Arg Ser Gly Tyr Phe Ser Met Asp Tyr 
1               5                   10  


<210>  116
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH5 Variable Heavy chain - VH (protein)

<400>  116

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 
            20                  25                  30          


Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Ala Ile Asn Ser Asp Gly Gly Ile Thr Tyr Tyr Leu Asp Thr Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 
                85                  90                  95      


Ala Arg His Arg Ser Gly Tyr Phe Ser Met Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ser 
        115                 


<210>  117
<211>  15
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH5 Variable Heavy chain - HCDR1 (DNA)

<400>  117
aactactaca tgagc                                                        15


<210>  118
<211>  51
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH5 Variable Heavy chain - HCDR2 (DNA)

<400>  118
gccattaaca gtgacggtgg catcacctac tacctggaca ccgtgaaggg c                51


<210>  119
<211>  30
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH5 Variable Heavy chain - HCDR3 (DNA)

<400>  119
cacaggagcg gctacttctc tatggactac                                        30


<210>  120
<211>  357
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH5 Variable Heavy chain - VH (DNA)

<400>  120
gaggtgcagc tggtggagtc tgggggaggc ttggtcaagc ctggaggatc cctgagactc       60

tcctgtgcag cctctggatt caccttcagt aactactaca tgagctgggt gcgccaggct      120

ccagggaagg ggctggagtg ggttgccgcc attaacagtg acggtggcat cacctactac      180

ctggacaccg tgaagggccg attcaccatc tccagggaca acgccaagaa caccctgtat      240

ctgcaaatga acagcctgag ggccgaggac acggccctgt attactgtgc gagacacagg      300

agcggctact tctctatgga ctactggggc cagggcaccc tggtcactgt ctcctca         357


<210>  121
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH5 Variable Heavy chain - HFR1 (protein)

<400>  121

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser 
            20                  25                  30  


<210>  122
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH5 Variable Heavy chain - HFR2 (protein)

<400>  122

Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala 
1               5                   10                  


<210>  123
<211>  32
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH5 Variable Heavy chain - HFR3 (protein)

<400>  123

Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln 
1               5                   10                  15      


Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg 
            20                  25                  30          


<210>  124
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH5 Variable Heavy chain - HFR4 (protein)

<400>  124

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
1               5                   10      


<210>  125
<211>  90
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH5 Variable Heavy chain - HFR1 (DNA)

<400>  125
gaggtgcagc tggtggagtc tgggggaggc ttggtcaagc ctggaggatc cctgagactc       60

tcctgtgcag cctctggatt caccttcagt                                        90


<210>  126
<211>  42
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH5 Variable Heavy chain - HFR2 (DNA)

<400>  126
tgggtgcgcc aggctccagg gaaggggctg gagtgggttg cc                          42


<210>  127
<211>  96
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH5 Variable Heavy chain - HFR3 (DNA)

<400>  127
cgattcacca tctccaggga caacgccaag aacaccctgt atctgcaaat gaacagcctg       60

agggccgagg acacggccct gtattactgt gcgaga                                 96


<210>  128
<211>  33
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab humanised VH5 Variable Heavy chain - HFR4 (DNA)

<400>  128
tggggccagg gcaccctggt cactgtctcc tca                                    33


<210>  129
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Chimeric Vk0 Variable light chain- LCDR1 (protein)

<400>  129

Lys Ala Ser Gln Asn Val Val Ser Ala Val Ala 
1               5                   10      


<210>  130
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Chimeric Vk0 Variable light chain- LCDR2 (protein)

<400>  130

Ser Ala Ser Asn Arg Tyr Thr 
1               5           


<210>  131
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Chimeric Vk0 Variable light chain- LCDR3 (protein)

<400>  131

Gln Gln Tyr Ser Asn Tyr Pro Trp Thr 
1               5                   


<210>  132
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Chimeric Vk0 Variable light chain- VL (protein)

<400>  132

Asp Ile Val Met Thr Gln Ser Gln Arg Phe Met Ser Thr Thr Val Gly 
1               5                   10                  15      


Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Val Ser Ala 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Met Gln Ser 
65                  70                  75                  80  


Glu Asp Leu Ala Asp Phe Phe Cys Gln Gln Tyr Ser Asn Tyr Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  133
<211>  33
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Chimeric Vk0 Variable light chain- LCDR1 (DNA)

<400>  133
aaggccagtc agaatgtggt ttctgctgtt gcc                                    33


<210>  134
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Chimeric Vk0 Variable light chain- LCDR2 (DNA)

<400>  134
tcagcatcca atcggtacac t                                                 21


<210>  135
<211>  27
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Chimeric Vk0 Variable light chain- LCDR3 (DNA)

<400>  135
caacaatata gcaactatcc gtggacg                                           27


<210>  136
<211>  321
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Chimeric Vk0 Variable light chain- VL (DNA)

<400>  136
gacattgtga tgacccagtc tcaaagattc atgtccacaa cagtaggaga cagggtcagc       60

atcacctgca aggccagtca gaatgtggtt tctgctgttg cctggtatca acagaaacca      120

ggacaatctc ctaaactact gatttactca gcatccaatc ggtacactgg agtccctgat      180

cgcttcacag gcagtggatc tgggacagat ttcactctca ccattagcaa tatgcagtct      240

gaagacctgg ctgatttttt ctgtcaacaa tatagcaact atccgtggac gttcggtgga      300

ggcaccaagc tggaaatcaa a                                                321


<210>  137
<211>  23
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Chimeric Vk0 Variable light chain- LFR1 (protein)

<400>  137

Asp Ile Val Met Thr Gln Ser Gln Arg Phe Met Ser Thr Thr Val Gly 
1               5                   10                  15      


Asp Arg Val Ser Ile Thr Cys 
            20              


<210>  138
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Chimeric Vk0 Variable light chain- LFR2 (protein)

<400>  138

Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr 
1               5                   10                  15  


<210>  139
<211>  32
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Chimeric Vk0 Variable light chain- LFR3 (protein)

<400>  139

Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr 
1               5                   10                  15      


Leu Thr Ile Ser Asn Met Gln Ser Glu Asp Leu Ala Asp Phe Phe Cys 
            20                  25                  30          


<210>  140
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Chimeric Vk0 Variable light chain- LFR4 (protein)

<400>  140

Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
1               5                   10  


<210>  141
<211>  69
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Chimeric Vk0 Variable light chain- LFR1 (DNA)

<400>  141
gacattgtga tgacccagtc tcaaagattc atgtccacaa cagtaggaga cagggtcagc       60

atcacctgc                                                               69


<210>  142
<211>  45
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Chimeric Vk0 Variable light chain- LFR2 (DNA)

<400>  142
tggtatcaac agaaaccagg acaatctcct aaactactga tttac                       45


<210>  143
<211>  96
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Chimeric Vk0 Variable light chain- LFR3 (DNA)

<400>  143
ggagtccctg atcgcttcac aggcagtgga tctgggacag atttcactct caccattagc       60

aatatgcagt ctgaagacct ggctgatttt ttctgt                                 96


<210>  144
<211>  30
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Chimeric Vk0 Variable light chain- LFR4 (DNA)

<400>  144
ttcggtggag gcaccaagct ggaaatcaaa                                        30


<210>  145
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk1 Variable light chain- LCDR1 (protein)

<400>  145

Lys Ala Ser Gln Asn Val Val Ser Ala Val Ala 
1               5                   10      


<210>  146
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk1 Variable light chain- LCDR2 (protein)

<400>  146

Ser Ala Ser Asn Arg Tyr Thr 
1               5           


<210>  147
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk1 Variable light chain- LCDR3 (protein)

<400>  147

Gln Gln Tyr Ser Asn Tyr Pro Trp Thr 
1               5                   


<210>  148
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk1 Variable light chain- VL (protein)

<400>  148

Asp Ile Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Val Ser Ala 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser 
65                  70                  75                  80  


Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Asn Tyr Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  149
<211>  33
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk1 Variable light chain- LCDR1 (DNA)

<400>  149
aaggcaagtc agaacgtggt gagtgctgtg gcc                                    33


<210>  150
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk1 Variable light chain- LCDR2 (DNA)

<400>  150
agcgcctcca acaggtacac c                                                 21


<210>  151
<211>  27
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk1 Variable light chain- LCDR3 (DNA)

<400>  151
caacagtaca gcaattaccc ttggacg                                           27


<210>  152
<211>  321
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk1 Variable light chain- VL (DNA)

<400>  152
gacatcgtga tgacccagtc tccatccttc ctgtctgcat ctgtaggaga cagagtcacc       60

atcacttgca aggcaagtca gaacgtggtg agtgctgtgg cctggtatca gcagaaacca      120

gggcaggctc ctaagctcct gatctatagc gcctccaaca ggtacaccgg ggtcccagac      180

aggttcaccg gcagtggatc tgggacagat ttcactctca ccatcagcag cctgcagagc      240

gaagatctgg cagactattt ctgtcaacag tacagcaatt acccttggac gttcggcggc      300

gggaccaagg tggaaatcaa a                                                321


<210>  153
<211>  23
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk1 Variable light chain- LFR1 (protein)

<400>  153

Asp Ile Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys 
            20              


<210>  154
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk1 Variable light chain- LFR2 (protein)

<400>  154

Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Leu Ile Tyr 
1               5                   10                  15  


<210>  155
<211>  32
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk1 Variable light chain- LFR3 (protein)

<400>  155

Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr 
1               5                   10                  15      


Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys 
            20                  25                  30          


<210>  156
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk1 Variable light chain- LFR4 (protein)

<400>  156

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
1               5                   10  


<210>  157
<211>  69
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk1 Variable light chain- LFR1 (DNA)

<400>  157
gacatcgtga tgacccagtc tccatccttc ctgtctgcat ctgtaggaga cagagtcacc       60

atcacttgc                                                               69


<210>  158
<211>  45
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk1 Variable light chain- LFR2 (DNA)

<400>  158
tggtatcagc agaaaccagg gcaggctcct aagctcctga tctat                       45


<210>  159
<211>  96
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk1 Variable light chain- LFR3 (DNA)

<400>  159
ggggtcccag acaggttcac cggcagtgga tctgggacag atttcactct caccatcagc       60

agcctgcaga gcgaagatct ggcagactat ttctgt                                 96


<210>  160
<211>  30
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk1 Variable light chain- LFR4 (DNA)

<400>  160
ttcggcggcg ggaccaaggt ggaaatcaaa                                        30


<210>  161
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk2 Variable light chain- LCDR1 (protein)

<400>  161

Lys Ala Ser Gln Asn Val Val Ser Ala Val Ala 
1               5                   10      


<210>  162
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk2 Variable light chain- LCDR2 (protein)

<400>  162

Ser Ala Ser Asn Arg Tyr Thr 
1               5           


<210>  163
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk2 Variable light chain- LCDR3 (protein)

<400>  163

Gln Gln Tyr Ser Asn Tyr Pro Trp Thr 
1               5                   


<210>  164
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk2 Variable light chain- VL (protein)

<400>  164

Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Val Ser Ala 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala 
65                  70                  75                  80  


Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Asn Tyr Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  165
<211>  33
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk2 Variable light chain- LCDR1 (DNA)

<400>  165
aaggcaagtc agaacgtggt gagtgctgtg gcc                                    33


<210>  166
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk2 Variable light chain- LCDR2 (DNA)

<400>  166
agcgcctcca acaggtacac c                                                 21


<210>  167
<211>  27
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk2 Variable light chain- LCDR3 (DNA)

<400>  167
caacagtaca gcaattaccc ttggacg                                           27


<210>  168
<211>  321
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk2 Variable light chain- VL (DNA)

<400>  168
gacatcgtga tgacccagtc tccatccagc ctgtctgcat ctgtaggaga cagagtcacc       60

atcacttgca aggcaagtca gaacgtggtg agtgctgtgg cctggtatca gcagaaacca      120

gggcaggctc ctaggctcct gatctatagc gcctccaaca ggtacaccgg ggtcccagac      180

aggttcaccg gcagtggatc tgggacagat ttcactctca ccatcagcag cctgcaggcc      240

gaagatctgg cagactattt ctgtcaacag tacagcaatt acccttggac gttcggcggc      300

gggaccaagg tggaaatcaa a                                                321


<210>  169
<211>  23
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk2 Variable light chain- LFR1 (protein)

<400>  169

Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys 
            20              


<210>  170
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk2 Variable light chain- LFR2 (protein)

<400>  170

Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr 
1               5                   10                  15  


<210>  171
<211>  32
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk2 Variable light chain- LFR3 (protein)

<400>  171

Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr 
1               5                   10                  15      


Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Leu Ala Asp Tyr Phe Cys 
            20                  25                  30          


<210>  172
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk2 Variable light chain- LFR4 (protein)

<400>  172

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
1               5                   10  


<210>  173
<211>  69
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk2 Variable light chain- LFR1 (DNA)

<400>  173
gacatcgtga tgacccagtc tccatccagc ctgtctgcat ctgtaggaga cagagtcacc       60

atcacttgc                                                               69


<210>  174
<211>  45
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk2 Variable light chain- LFR2 (DNA)

<400>  174
tggtatcagc agaaaccagg gcaggctcct aggctcctga tctat                       45


<210>  175
<211>  96
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk2 Variable light chain- LFR3 (DNA)

<400>  175
ggggtcccag acaggttcac cggcagtgga tctgggacag atttcactct caccatcagc       60

agcctgcagg ccgaagatct ggcagactat ttctgt                                 96


<210>  176
<211>  30
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk2 Variable light chain- LFR4 (DNA)

<400>  176
ttcggcggcg ggaccaaggt ggaaatcaaa                                        30


<210>  177
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk3 Variable light chain- LCDR1 (protein)

<400>  177

Lys Ala Ser Gln Asn Val Val Ser Ala Val Ala 
1               5                   10      


<210>  178
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk3 Variable light chain- LCDR2 (protein)

<400>  178

Ser Ala Ser Asn Arg Tyr Thr 
1               5           


<210>  179
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk3 Variable light chain- LCDR3 (protein)

<400>  179

Gln Gln Tyr Ser Asn Tyr Pro Trp Thr 
1               5                   


<210>  180
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk3 Variable light chain- VL (protein)

<400>  180

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Val Ser Ala 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala 
65                  70                  75                  80  


Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Asn Tyr Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  181
<211>  33
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk3 Variable light chain- LCDR1 (DNA)

<400>  181
aaggcaagtc agaacgtggt gagtgctgtg gcc                                    33


<210>  182
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk3 Variable light chain- LCDR2 (DNA)

<400>  182
agcgcctcca acaggtacac c                                                 21


<210>  183
<211>  27
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk3 Variable light chain- LCDR3 (DNA)

<400>  183
caacagtaca gcaattaccc ttggacg                                           27


<210>  184
<211>  321
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk3 Variable light chain- VL (DNA)

<400>  184
gacatccaga tgacccagtc tccatccagc ctgtctgcat ctgtaggaga cagagtcacc       60

atcacttgca aggcaagtca gaacgtggtg agtgctgtgg cctggtatca gcagaaacca      120

gggcaggctc ctaggctcct gatctatagc gcctccaaca ggtacaccgg ggtcccagac      180

aggttcagcg gcagtggatc tgggacagat ttcactctca ccatcagcag cctgcaggcc      240

gaagatctgg cagactattt ctgtcaacag tacagcaatt acccttggac gttcggcggc      300

gggaccaagg tggaaatcaa a                                                321


<210>  185
<211>  23
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk3 Variable light chain- LFR1 (protein)

<400>  185

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys 
            20              


<210>  186
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk3 Variable light chain- LFR2 (protein)

<400>  186

Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr 
1               5                   10                  15  


<210>  187
<211>  32
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk3 Variable light chain- LFR3 (protein)

<400>  187

Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 
1               5                   10                  15      


Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Leu Ala Asp Tyr Phe Cys 
            20                  25                  30          


<210>  188
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk3 Variable light chain- LFR4 (protein)

<400>  188

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
1               5                   10  


<210>  189
<211>  69
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk3 Variable light chain- LFR1 (DNA)

<400>  189
gacatccaga tgacccagtc tccatccagc ctgtctgcat ctgtaggaga cagagtcacc       60

atcacttgc                                                               69


<210>  190
<211>  45
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk3 Variable light chain- LFR2 (DNA)

<400>  190
tggtatcagc agaaaccagg gcaggctcct aggctcctga tctat                       45


<210>  191
<211>  96
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk3 Variable light chain- LFR3 (DNA)

<400>  191
ggggtcccag acaggttcag cggcagtgga tctgggacag atttcactct caccatcagc       60

agcctgcagg ccgaagatct ggcagactat ttctgt                                 96


<210>  192
<211>  30
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk3 Variable light chain- LFR4 (DNA)

<400>  192
ttcggcggcg ggaccaaggt ggaaatcaaa                                        30


<210>  193
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk4 Variable light chain- LCDR1 (protein)

<400>  193

Lys Ala Ser Gln Asn Val Val Ser Ala Val Ala 
1               5                   10      


<210>  194
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk4 Variable light chain- LCDR2 (protein)

<400>  194

Ser Ala Ser Asn Arg Tyr Thr 
1               5           


<210>  195
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk4 Variable light chain- LCDR3 (protein)

<400>  195

Gln Gln Tyr Ser Asn Tyr Pro Trp Thr 
1               5                   


<210>  196
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk4 Variable light chain- VL (protein)

<400>  196

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Val Ser Ala 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala 
65                  70                  75                  80  


Glu Asp Leu Ala Asp Tyr Tyr Cys Gln Gln Tyr Ser Asn Tyr Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  197
<211>  33
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk4 Variable light chain- LCDR1 (DNA)

<400>  197
aaggcaagtc agaacgtggt gagtgctgtg gcc                                    33


<210>  198
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk4 Variable light chain- LCDR2 (DNA)

<400>  198
agcgcctcca acaggtacac c                                                 21


<210>  199
<211>  27
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk4 Variable light chain- LCDR3 (DNA)

<400>  199
caacagtaca gcaattaccc ttggacg                                           27


<210>  200
<211>  321
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk4 Variable light chain - VL (DNA)

<400>  200
gacatccaga tgacccagtc tccatccagc ctgtctgcat ctgtaggaga cagagtcacc       60

atcacttgca aggcaagtca gaacgtggtg agtgctgtgg cctggtatca gcagaaacca      120

gggcaggctc ctaggctcct gatctatagc gcctccaaca ggtacaccgg ggtcccagac      180

aggttcagcg gcagtggatc tgggacagat ttcactctca ccatcagcag cctgcaggcc      240

gaagatctgg cagactatta ctgtcaacag tacagcaatt acccttggac gttcggcggc      300

gggaccaagg tggaaatcaa a                                                321


<210>  201
<211>  23
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk4 Variable light chain- LFR1 (protein)

<400>  201

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys 
            20              


<210>  202
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk4 Variable light chain- LFR2 (protein)

<400>  202

Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr 
1               5                   10                  15  


<210>  203
<211>  32
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk4 Variable light chain- LFR3 (protein)

<400>  203

Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 
1               5                   10                  15      


Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Leu Ala Asp Tyr Tyr Cys 
            20                  25                  30          


<210>  204
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk4 Variable light chain- LFR4 (protein)

<400>  204

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
1               5                   10  


<210>  205
<211>  69
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk4 Variable light chain - LFR1 (DNA)

<400>  205
gacatccaga tgacccagtc tccatccagc ctgtctgcat ctgtaggaga cagagtcacc       60

atcacttgc                                                               69


<210>  206
<211>  45
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk4 Variable light chain - LFR2 (DNA)

<400>  206
tggtatcagc agaaaccagg gcaggctcct aggctcctga tctat                       45


<210>  207
<211>  96
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk4 Variable light chain - LFR3 (DNA)

<400>  207
ggggtcccag acaggttcag cggcagtgga tctgggacag atttcactct caccatcagc       60

agcctgcagg ccgaagatct ggcagactat tactgt                                 96


<210>  208
<211>  30
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk4 Variable light chain - LFR4 (DNA)

<400>  208
ttcggcggcg ggaccaaggt ggaaatcaaa                                        30


<210>  209
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk5 Variable light chain - LCDR1 (protein)

<400>  209

Lys Ala Ser Gln Asn Val Val Ser Ala Val Ala 
1               5                   10      


<210>  210
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk5 Variable light chain - LCDR2 (protein)

<400>  210

Ser Ala Ser Asn Arg Tyr Thr 
1               5           


<210>  211
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk5 Variable light chain - LCDR3 (protein)

<400>  211

Gln Gln Tyr Ser Asn Tyr Pro Trp Thr 
1               5                   


<210>  212
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk5 Variable light chain - VL (protein)

<400>  212

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Val Ser Ala 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Arg Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala 
65                  70                  75                  80  


Glu Asp Leu Ala Asp Tyr Tyr Cys Gln Gln Tyr Ser Asn Tyr Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  213
<211>  33
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk5 Variable light chain - LCDR1 (DNA)

<400>  213
aaggcaagtc agaacgtggt gagtgctgtg gcc                                    33


<210>  214
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk5 Variable light chain - LCDR2 (DNA)

<400>  214
agcgcctcca acaggtacac c                                                 21


<210>  215
<211>  27
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk5 Variable light chain - LCDR3 (DNA)

<400>  215
caacagtaca gcaattaccc ttggacg                                           27


<210>  216
<211>  321
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk5 Variable light chain - VL (DNA)

<400>  216
gacatccaga tgacccagtc tccatccagc ctgtctgcat ctgtaggaga cagagtcacc       60

atcacttgca aggcaagtca gaacgtggtg agtgctgtgg cctggtatca gcagaaacca      120

gggcaggctc ctaggaggct gatctatagc gcctccaaca ggtacaccgg ggtcccagac      180

aggttcagcg gcagtggatc tgggacagat ttcactctca ccatcagcag cctgcaggcc      240

gaagatctgg cagactatta ctgtcaacag tacagcaatt acccttggac gttcggcggc      300

gggaccaagg tggaaatcaa a                                                321


<210>  217
<211>  23
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk5 Variable light chain - LFR1 (protein)

<400>  217

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys 
            20              


<210>  218
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk5 Variable light chain - LFR2 (protein)

<400>  218

Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Arg Leu Ile Tyr 
1               5                   10                  15  


<210>  219
<211>  32
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk5 Variable light chain - LFR3 (protein)

<400>  219

Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 
1               5                   10                  15      


Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Leu Ala Asp Tyr Tyr Cys 
            20                  25                  30          


<210>  220
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk5 Variable light chain - LFR4 (protein)

<400>  220

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
1               5                   10  


<210>  221
<211>  69
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk5 Variable light chain - LFR1 (DNA)

<400>  221
gacatccaga tgacccagtc tccatccagc ctgtctgcat ctgtaggaga cagagtcacc       60

atcacttgc                                                               69


<210>  222
<211>  45
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk5 Variable light chain - LFR2 (DNA)

<400>  222
tggtatcagc agaaaccagg gcaggctcct aggaggctga tctat                       45


<210>  223
<211>  96
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk5 Variable light chain - LFR3 (DNA)

<400>  223
ggggtcccag acaggttcag cggcagtgga tctgggacag atttcactct caccatcagc       60

agcctgcagg ccgaagatct ggcagactat tactgt                                 96


<210>  224
<211>  30
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Girentuximab Humanised Vk5 Variable light chain - LFR4 (DNA)

<400>  224
ttcggcggcg ggaccaaggt ggaaatcaaa                                        30


<210>  225
<211>  330
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab unmodified human IgG1 constant chain region - IgG1 
       HC (protein)

<400>  225

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 
1               5                   10                  15      


Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 
            20                  25                  30          


Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 
        35                  40                  45              


Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 
    50                  55                  60                  


Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 
65                  70                  75                  80  


Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 
                85                  90                  95      


Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 
            100                 105                 110         


Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 
        115                 120                 125             


Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 
    130                 135                 140                 


Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 
145                 150                 155                 160 


Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 
                165                 170                 175     


Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 
            180                 185                 190         


His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 
        195                 200                 205             


Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 
    210                 215                 220                 


Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu 
225                 230                 235                 240 


Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 
                245                 250                 255     


Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 
            260                 265                 270         


Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 
        275                 280                 285             


Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 
    290                 295                 300                 


Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 
305                 310                 315                 320 


Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 
                325                 330 


<210>  226
<211>  330
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab modified human IgG1 constant chain region - IgG1 
       H310A H435Q HC (protein)

<400>  226

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 
1               5                   10                  15      


Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 
            20                  25                  30          


Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 
        35                  40                  45              


Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 
    50                  55                  60                  


Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 
65                  70                  75                  80  


Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 
                85                  90                  95      


Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 
            100                 105                 110         


Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 
        115                 120                 125             


Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 
    130                 135                 140                 


Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 
145                 150                 155                 160 


Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 
                165                 170                 175     


Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 
            180                 185                 190         


Ala Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 
        195                 200                 205             


Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 
    210                 215                 220                 


Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu 
225                 230                 235                 240 


Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 
                245                 250                 255     


Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 
            260                 265                 270         


Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 
        275                 280                 285             


Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 
    290                 295                 300                 


Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn Gln Tyr Thr 
305                 310                 315                 320 


Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 
                325                 330 


<210>  227
<211>  327
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab modified human IgG4 constant chain region - IgG4 
       S228P L235E HC (protein)

<400>  227

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg 
1               5                   10                  15      


Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 
            20                  25                  30          


Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 
        35                  40                  45              


Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 
    50                  55                  60                  


Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr 
65                  70                  75                  80  


Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys 
                85                  90                  95      


Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro 
            100                 105                 110         


Glu Phe Glu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 
        115                 120                 125             


Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 
    130                 135                 140                 


Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp 
145                 150                 155                 160 


Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe 
                165                 170                 175     


Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 
            180                 185                 190         


Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu 
        195                 200                 205             


Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 
    210                 215                 220                 


Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys 
225                 230                 235                 240 


Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 
                245                 250                 255     


Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 
            260                 265                 270         


Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 
        275                 280                 285             


Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser 
    290                 295                 300                 


Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 
305                 310                 315                 320 


Leu Ser Leu Ser Leu Gly Lys 
                325         


<210>  228
<211>  327
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab modified human IgG4 constant chain region - IgG4 
       S228P L235E H310A H435Q HC (protein)

<400>  228

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg 
1               5                   10                  15      


Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 
            20                  25                  30          


Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 
        35                  40                  45              


Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 
    50                  55                  60                  


Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr 
65                  70                  75                  80  


Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys 
                85                  90                  95      


Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro 
            100                 105                 110         


Glu Phe Glu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 
        115                 120                 125             


Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 
    130                 135                 140                 


Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp 
145                 150                 155                 160 


Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe 
                165                 170                 175     


Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu Ala Gln Asp 
            180                 185                 190         


Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu 
        195                 200                 205             


Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 
    210                 215                 220                 


Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys 
225                 230                 235                 240 


Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 
                245                 250                 255     


Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 
            260                 265                 270         


Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 
        275                 280                 285             


Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser 
    290                 295                 300                 


Cys Ser Val Met His Glu Ala Leu His Asn Gln Tyr Thr Gln Lys Ser 
305                 310                 315                 320 


Leu Ser Leu Ser Leu Gly Lys 
                325         


<210>  229
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab kappa light chain constant region - Human ? LC 
       constant region (protein)

<400>  229

Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 
1               5                   10                  15      


Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 
            20                  25                  30          


Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 
        35                  40                  45              


Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 
    50                  55                  60                  


Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 
65                  70                  75                  80  


Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 
                85                  90                  95      


Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 
            100                 105         


<210>  230
<211>  449
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Girentuximab native IgG1 allotype Gm (1,17) VH4 heavy chain - 
       IgG1 VH4 heavy chain (protein)

<400>  230

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 
            20                  25                  30          


Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Leu Val 
        35                  40                  45              


Ala Ala Ile Asn Ser Asp Gly Gly Ile Thr Tyr Tyr Leu Asp Thr Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 
                85                  90                  95      


Ala Arg His Arg Ser Gly Tyr Phe Ser Met Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe 
        115                 120                 125             


Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu 
    130                 135                 140                 


Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 
145                 150                 155                 160 


Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 
                165                 170                 175     


Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 
            180                 185                 190         


Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro 
        195                 200                 205             


Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys 
    210                 215                 220                 


Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 
225                 230                 235                 240 


Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 
                245                 250                 255     


Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 
            260                 265                 270         


Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 
        275                 280                 285             


Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val 
    290                 295                 300                 


Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 
305                 310                 315                 320 


Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 
                325                 330                 335     


Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 
            340                 345                 350         


Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr 
        355                 360                 365             


Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 
    370                 375                 380                 


Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 
385                 390                 395                 400 


Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 
                405                 410                 415     


Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu 
            420                 425                 430         


Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 
        435                 440                 445             


Lys 
    


<210>  231
<211>  449
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  hGirentuximab IgG1 allotype Gm (1,17) RADmAb VH4 heavy chain - 
       FcRn-null IgG1 allotype H130A H435Q (protein)

<400>  231

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 
            20                  25                  30          


Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Leu Val 
        35                  40                  45              


Ala Ala Ile Asn Ser Asp Gly Gly Ile Thr Tyr Tyr Leu Asp Thr Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 
                85                  90                  95      


Ala Arg His Arg Ser Gly Tyr Phe Ser Met Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe 
        115                 120                 125             


Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu 
    130                 135                 140                 


Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 
145                 150                 155                 160 


Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 
                165                 170                 175     


Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 
            180                 185                 190         


Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro 
        195                 200                 205             


Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys 
    210                 215                 220                 


Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 
225                 230                 235                 240 


Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 
                245                 250                 255     


Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 
            260                 265                 270         


Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 
        275                 280                 285             


Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val 
    290                 295                 300                 


Val Ser Val Leu Thr Val Leu Ala Gln Asp Trp Leu Asn Gly Lys Glu 
305                 310                 315                 320 


Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 
                325                 330                 335     


Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 
            340                 345                 350         


Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr 
        355                 360                 365             


Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 
    370                 375                 380                 


Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 
385                 390                 395                 400 


Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 
                405                 410                 415     


Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu 
            420                 425                 430         


Ala Leu His Asn Gln Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 
        435                 440                 445             


Lys 
    


<210>  232
<211>  446
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  hGirentuximab  IgG4  RADmAb  VH4 heavy chain - FcR?-null IgG4 
       S228P L235E

(protein)

<400>  232

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 
            20                  25                  30          


Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Leu Val 
        35                  40                  45              


Ala Ala Ile Asn Ser Asp Gly Gly Ile Thr Tyr Tyr Leu Asp Thr Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 
                85                  90                  95      


Ala Arg His Arg Ser Gly Tyr Phe Ser Met Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe 
        115                 120                 125             


Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu 
    130                 135                 140                 


Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 
145                 150                 155                 160 


Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 
                165                 170                 175     


Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 
            180                 185                 190         


Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro 
        195                 200                 205             


Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro 
    210                 215                 220                 


Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser Val Phe 
225                 230                 235                 240 


Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro 
                245                 250                 255     


Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val 
            260                 265                 270         


Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr 
        275                 280                 285             


Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val 
    290                 295                 300                 


Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys 
305                 310                 315                 320 


Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser 
                325                 330                 335     


Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro 
            340                 345                 350         


Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val 
        355                 360                 365             


Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly 
    370                 375                 380                 


Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp 
385                 390                 395                 400 


Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp 
                405                 410                 415     


Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His 
            420                 425                 430         


Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 
        435                 440                 445     


<210>  233
<211>  446
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  hGirentuximab IgG4 RADmAb  VH4 heavy chain - FcRn+FcR?-null IgG4 
       S228P L235E H310A H435Q (protein)

<400>  233

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 
            20                  25                  30          


Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Leu Val 
        35                  40                  45              


Ala Ala Ile Asn Ser Asp Gly Gly Ile Thr Tyr Tyr Leu Asp Thr Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 
                85                  90                  95      


Ala Arg His Arg Ser Gly Tyr Phe Ser Met Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe 
        115                 120                 125             


Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu 
    130                 135                 140                 


Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 
145                 150                 155                 160 


Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 
                165                 170                 175     


Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 
            180                 185                 190         


Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro 
        195                 200                 205             


Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro 
    210                 215                 220                 


Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser Val Phe 
225                 230                 235                 240 


Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro 
                245                 250                 255     


Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val 
            260                 265                 270         


Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr 
        275                 280                 285             


Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val 
    290                 295                 300                 


Leu Thr Val Leu Ala Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys 
305                 310                 315                 320 


Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser 
                325                 330                 335     


Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro 
            340                 345                 350         


Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val 
        355                 360                 365             


Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly 
    370                 375                 380                 


Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp 
385                 390                 395                 400 


Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp 
                405                 410                 415     


Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His 
            420                 425                 430         


Asn Gln Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 
        435                 440                 445     


<210>  234
<211>  214
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  hGirentuximab V? Light Chain - V? Light Chain (protein)

<400>  234

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Val Ser Ala 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala 
65                  70                  75                  80  


Glu Asp Leu Ala Asp Tyr Tyr Cys Gln Gln Tyr Ser Asn Tyr Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 
            100                 105                 110         


Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 
        115                 120                 125             


Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 
    130                 135                 140                 


Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 
145                 150                 155                 160 


Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 
                165                 170                 175     


Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 
            180                 185                 190         


Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 
        195                 200                 205             


Phe Asn Arg Gly Glu Cys 
    210                 


<210>  235
<211>  330
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANT4044/ANT4044-A2 unmodified human IgG1 heavy chain constant 
       region -  IgG1 HC (protein)

<400>  235

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 
1               5                   10                  15      


Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 
            20                  25                  30          


Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 
        35                  40                  45              


Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 
    50                  55                  60                  


Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 
65                  70                  75                  80  


Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 
                85                  90                  95      


Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 
            100                 105                 110         


Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 
        115                 120                 125             


Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 
    130                 135                 140                 


Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 
145                 150                 155                 160 


Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 
                165                 170                 175     


Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 
            180                 185                 190         


His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 
        195                 200                 205             


Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 
    210                 215                 220                 


Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 
225                 230                 235                 240 


Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 
                245                 250                 255     


Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 
            260                 265                 270         


Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 
        275                 280                 285             


Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 
    290                 295                 300                 


Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 
305                 310                 315                 320 


Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 
                325                 330 


<210>  236
<211>  330
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANT4044/ANT4044-A2 modified human IgG1 heavy chain constant 
       region - IgG1 H310A H435Q HC (protein)

<400>  236

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 
1               5                   10                  15      


Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 
            20                  25                  30          


Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 
        35                  40                  45              


Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 
    50                  55                  60                  


Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 
65                  70                  75                  80  


Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 
                85                  90                  95      


Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 
            100                 105                 110         


Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 
        115                 120                 125             


Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 
    130                 135                 140                 


Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 
145                 150                 155                 160 


Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 
                165                 170                 175     


Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 
            180                 185                 190         


Ala Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 
        195                 200                 205             


Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 
    210                 215                 220                 


Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 
225                 230                 235                 240 


Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 
                245                 250                 255     


Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 
            260                 265                 270         


Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 
        275                 280                 285             


Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 
    290                 295                 300                 


Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn Gln Tyr Thr 
305                 310                 315                 320 


Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 
                325                 330 


<210>  237
<211>  327
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANT4044/ANT4044-A2 modified human IgG4 constant chain region - 
       IgG4 S228P L235E H310A H435Q HC (protein)

<400>  237

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg 
1               5                   10                  15      


Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 
            20                  25                  30          


Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 
        35                  40                  45              


Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 
    50                  55                  60                  


Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr 
65                  70                  75                  80  


Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys 
                85                  90                  95      


Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro 
            100                 105                 110         


Glu Phe Glu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 
        115                 120                 125             


Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 
    130                 135                 140                 


Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp 
145                 150                 155                 160 


Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe 
                165                 170                 175     


Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu Ala Gln Asp 
            180                 185                 190         


Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu 
        195                 200                 205             


Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 
    210                 215                 220                 


Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys 
225                 230                 235                 240 


Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 
                245                 250                 255     


Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 
            260                 265                 270         


Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 
        275                 280                 285             


Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser 
    290                 295                 300                 


Cys Ser Val Met His Glu Ala Leu His Asn Gln Tyr Thr Gln Lys Ser 
305                 310                 315                 320 


Leu Ser Leu Ser Leu Gly Lys 
                325         


<210>  238
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANT4044/ANT4044-A2 kappa light chain constant region 	Human Kappa
       LC constant region (protein)

<400>  238

Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 
1               5                   10                  15      


Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 
            20                  25                  30          


Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 
        35                  40                  45              


Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 
    50                  55                  60                  


Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 
65                  70                  75                  80  


Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 
                85                  90                  95      


Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 
            100                 105         


<210>  239
<211>  445
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANT4044 RADmAb IgG1 heavy chain (HuX592r) - FcRn-null, IgG1 
       allotype G1m(3) H310A H435Q (protein)

<400>  239

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr 
            20                  25                  30          


Thr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asn Ile Asn Pro Asn Asn Gly Gly Thr Thr Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Glu Asp Arg Val Thr Ile Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Ala Gly Trp Asn Phe Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr 
            100                 105                 110         


Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro 
        115                 120                 125             


Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val 
    130                 135                 140                 


Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala 
145                 150                 155                 160 


Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly 
                165                 170                 175     


Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly 
            180                 185                 190         


Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys 
        195                 200                 205             


Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys 
    210                 215                 220                 


Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 
225                 230                 235                 240 


Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 
                245                 250                 255     


Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 
            260                 265                 270         


Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 
        275                 280                 285             


Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 
    290                 295                 300                 


Thr Val Leu Ala Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 
305                 310                 315                 320 


Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 
                325                 330                 335     


Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser 
            340                 345                 350         


Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys 
        355                 360                 365             


Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln 
    370                 375                 380                 


Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 
385                 390                 395                 400 


Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln 
                405                 410                 415     


Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 
            420                 425                 430         


Gln Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 
        435                 440                 445 


<210>  240
<211>  442
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANT4044 RADmAb IgG4 heavy chain - FcRn+FcR Gamma-null, IgG4 S228P
       L235E H310A H435Q (protein)

<400>  240

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr 
            20                  25                  30          


Thr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asn Ile Asn Pro Asn Asn Gly Gly Thr Thr Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Glu Asp Arg Val Thr Ile Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Ala Gly Trp Asn Phe Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr 
            100                 105                 110         


Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro 
        115                 120                 125             


Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val 
    130                 135                 140                 


Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala 
145                 150                 155                 160 


Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly 
                165                 170                 175     


Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly 
            180                 185                 190         


Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys 
        195                 200                 205             


Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys 
    210                 215                 220                 


Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 
225                 230                 235                 240 


Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 
                245                 250                 255     


Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp 
            260                 265                 270         


Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 
        275                 280                 285             


Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 
    290                 295                 300                 


Ala Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 
305                 310                 315                 320 


Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 
                325                 330                 335     


Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu 
            340                 345                 350         


Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 
        355                 360                 365             


Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 
    370                 375                 380                 


Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 
385                 390                 395                 400 


Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn 
                405                 410                 415     


Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn Gln Tyr Thr 
            420                 425                 430         


Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 
        435                 440         


<210>  241
<211>  445
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANT4044-A2 RADmAb IgG1 heavy chain - FcRn-null, IgG1 H310A H435Q 
       (protein)

<400>  241

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr 
            20                  25                  30          


Thr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asn Ile Asn Pro Asn Asn Gly Gly Thr Thr Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Glu Asp Arg Val Thr Ile Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Ala Tyr Trp Leu Phe Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr 
            100                 105                 110         


Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro 
        115                 120                 125             


Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val 
    130                 135                 140                 


Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala 
145                 150                 155                 160 


Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly 
                165                 170                 175     


Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly 
            180                 185                 190         


Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys 
        195                 200                 205             


Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys 
    210                 215                 220                 


Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 
225                 230                 235                 240 


Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 
                245                 250                 255     


Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 
            260                 265                 270         


Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 
        275                 280                 285             


Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 
    290                 295                 300                 


Thr Val Leu Ala Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 
305                 310                 315                 320 


Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 
                325                 330                 335     


Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser 
            340                 345                 350         


Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys 
        355                 360                 365             


Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln 
    370                 375                 380                 


Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 
385                 390                 395                 400 


Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln 
                405                 410                 415     


Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 
            420                 425                 430         


Gln Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 
        435                 440                 445 


<210>  242
<211>  442
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANT4044-A2 RADmAb IgG4 heavy chain - FcRn+FcR Gamma-null IgG4 
       S228P L235E H310A H435Q

(protein)

<400>  242

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr 
            20                  25                  30          


Thr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asn Ile Asn Pro Asn Asn Gly Gly Thr Thr Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Glu Asp Arg Val Thr Ile Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Ala Tyr Trp Leu Phe Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr 
            100                 105                 110         


Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro 
        115                 120                 125             


Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val 
    130                 135                 140                 


Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala 
145                 150                 155                 160 


Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly 
                165                 170                 175     


Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly 
            180                 185                 190         


Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys 
        195                 200                 205             


Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys 
    210                 215                 220                 


Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 
225                 230                 235                 240 


Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 
                245                 250                 255     


Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp 
            260                 265                 270         


Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 
        275                 280                 285             


Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 
    290                 295                 300                 


Ala Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 
305                 310                 315                 320 


Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 
                325                 330                 335     


Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu 
            340                 345                 350         


Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 
        355                 360                 365             


Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 
    370                 375                 380                 


Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 
385                 390                 395                 400 


Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn 
                405                 410                 415     


Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn Gln Tyr Thr 
            420                 425                 430         


Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 
        435                 440         


<210>  243
<211>  214
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANT4044-ANT4044-A2 Vk Light chain - Vk Light chain (protein)

<400>  243

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Ala 
            20                  25                  30          


Val Asp Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Leu 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala 
            100                 105                 110         


Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 
        115                 120                 125             


Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 
    130                 135                 140                 


Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 
145                 150                 155                 160 


Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 
                165                 170                 175     


Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 
            180                 185                 190         


Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 
        195                 200                 205             


Phe Asn Arg Gly Glu Cys 
    210                 


